Agammaglobulinemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major agammaglobulinemia markets are expected to exhibit a CAGR of 6.9% during 2024-2034.
The agammaglobulinemia market has been comprehensively analyzed in IMARC's new report titled "Agammaglobulinemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Agammaglobulinemia refers to a rare genetic disorder that affects the immune system, particularly the body's ability to produce immunoglobulins or antibodies. These antibodies are crucial for fighting off pathogens, and their absence or reduced levels make patients highly susceptible to bacterial and viral infections. The symptoms often manifest in early childhood, usually within the first few months after birth. Infants suffering from the ailment may experience recurrent respiratory and skin infections, persistent diarrhea, and a general failure to thrive. The diagnosis of agammaglobulinemia typically involves clinical evaluation, medical history assessment, and laboratory tests. A blood workup is also utilized to measure immunoglobulin (antibody) levels, particularly IgG, IgA, and IgM. Low or absent levels of these immunoglobulins, along with a diminished number of B cells, confirm the diagnosis. Genetic testing may also be conducted to identify mutations in genes, such as the Bruton's tyrosine kinase (BTK) gene, which is commonly associated with X-linked agammaglobulinemia.
The increasing cases of genetic variations, which can result in an inability to produce sufficient levels of antibodies, are primarily driving the agammaglobulinemia market. In addition to this, the inflating utilization of advanced therapeutic interventions, such as intravenous immunoglobulin (IVIG) infusions and antibiotic prophylaxis, to manage infections and mitigate the disease's impact is also creating a positive outlook for the market. Moreover, the widespread adoption of supportive treatments, including regular medical evaluations, lung function assessments, and nutritional guidance, to enhance patients' overall well-being is further bolstering the market growth. Apart from this, the rising usage of hematopoietic stem cell transplantation (HSCT) procedures, which involve replacing faulty bone marrow cells with healthy ones, thereby restoring the production of functional B cells and immune competence, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of advanced diagnostic techniques, including flow cytometry and molecular genetic testing, to provide early detection and accurate diagnosis of the ailment, thus enhancing the treatment regimen, is also augmenting the market growth. Furthermore, the escalating application of gene therapies that target the BTK gene's mutations, aiming to restore normal immune function in patients is expected to drive the agammaglobulinemia market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the agammaglobulinemia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for agammaglobulinemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the agammaglobulinemia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the agammaglobulinemia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the agammaglobulinemia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape
This report also provides a detailed analysis of the current agammaglobulinemia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report
Key Questions Answered in this Report
Market Insights
How has the agammaglobulinemia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the agammaglobulinemia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the agammaglobulinemia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of agammaglobulinemia across the seven major markets?
What is the number of prevalent cases (2018-2034) of agammaglobulinemia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of agammaglobulinemia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with agammaglobulinemia across the seven major markets?
What is the size of the agammaglobulinemia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of agammaglobulinemia?
What will be the growth rate of patients across the seven major markets?
Agammaglobulinemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for agammaglobulinemia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the agammaglobulinemia market?
What are the key regulatory events related to the agammaglobulinemia market?
What is the structure of clinical trial landscape by status related to the agammaglobulinemia market?
What is the structure of clinical trial landscape by phase related to the agammaglobulinemia market?
What is the structure of clinical trial landscape by route of administration related to the agammaglobulinemia market?
The agammaglobulinemia market has been comprehensively analyzed in IMARC's new report titled "Agammaglobulinemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Agammaglobulinemia refers to a rare genetic disorder that affects the immune system, particularly the body's ability to produce immunoglobulins or antibodies. These antibodies are crucial for fighting off pathogens, and their absence or reduced levels make patients highly susceptible to bacterial and viral infections. The symptoms often manifest in early childhood, usually within the first few months after birth. Infants suffering from the ailment may experience recurrent respiratory and skin infections, persistent diarrhea, and a general failure to thrive. The diagnosis of agammaglobulinemia typically involves clinical evaluation, medical history assessment, and laboratory tests. A blood workup is also utilized to measure immunoglobulin (antibody) levels, particularly IgG, IgA, and IgM. Low or absent levels of these immunoglobulins, along with a diminished number of B cells, confirm the diagnosis. Genetic testing may also be conducted to identify mutations in genes, such as the Bruton's tyrosine kinase (BTK) gene, which is commonly associated with X-linked agammaglobulinemia.
The increasing cases of genetic variations, which can result in an inability to produce sufficient levels of antibodies, are primarily driving the agammaglobulinemia market. In addition to this, the inflating utilization of advanced therapeutic interventions, such as intravenous immunoglobulin (IVIG) infusions and antibiotic prophylaxis, to manage infections and mitigate the disease's impact is also creating a positive outlook for the market. Moreover, the widespread adoption of supportive treatments, including regular medical evaluations, lung function assessments, and nutritional guidance, to enhance patients' overall well-being is further bolstering the market growth. Apart from this, the rising usage of hematopoietic stem cell transplantation (HSCT) procedures, which involve replacing faulty bone marrow cells with healthy ones, thereby restoring the production of functional B cells and immune competence, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of advanced diagnostic techniques, including flow cytometry and molecular genetic testing, to provide early detection and accurate diagnosis of the ailment, thus enhancing the treatment regimen, is also augmenting the market growth. Furthermore, the escalating application of gene therapies that target the BTK gene's mutations, aiming to restore normal immune function in patients is expected to drive the agammaglobulinemia market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the agammaglobulinemia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for agammaglobulinemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the agammaglobulinemia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the agammaglobulinemia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the agammaglobulinemia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape
This report also provides a detailed analysis of the current agammaglobulinemia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report
Key Questions Answered in this Report
Market Insights
How has the agammaglobulinemia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the agammaglobulinemia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the agammaglobulinemia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of agammaglobulinemia across the seven major markets?
What is the number of prevalent cases (2018-2034) of agammaglobulinemia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of agammaglobulinemia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with agammaglobulinemia across the seven major markets?
What is the size of the agammaglobulinemia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of agammaglobulinemia?
What will be the growth rate of patients across the seven major markets?
Agammaglobulinemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for agammaglobulinemia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the agammaglobulinemia market?
What are the key regulatory events related to the agammaglobulinemia market?
What is the structure of clinical trial landscape by status related to the agammaglobulinemia market?
What is the structure of clinical trial landscape by phase related to the agammaglobulinemia market?
What is the structure of clinical trial landscape by route of administration related to the agammaglobulinemia market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 AGAMMAGLOBULINEMIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 AGAMMAGLOBULINEMIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 AGAMMAGLOBULINEMIA - EPIDEMIOLOGY AND PATIENT POPULATION
77.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 AGAMMAGLOBULINEMIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 AGAMMAGLOBULINEMIA - UNMET NEEDS
10 AGAMMAGLOBULINEMIA - KEY ENDPOINTS OF TREATMENT
11 AGAMMAGLOBULINEMIA - MARKETED PRODUCTS
11.1 List of Agammaglobulinemia Marketed Drugs Across the Top 7 Markets
11.1.1 Panzyga (Immune globulin 10%) - Octapharma
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 HyQvia (Immune globulin) -Takeda
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 AGAMMAGLOBULINEMIA - PIPELINE DRUGS
12.1 List of Agammaglobulinemia Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. AGAMMAGLOBULINEMIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. AGAMMAGLOBULINEMIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 AGAMMAGLOBULINEMIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Agammaglobulinemia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Agammaglobulinemia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Agammaglobulinemia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Agammaglobulinemia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Agammaglobulinemia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Agammaglobulinemia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Agammaglobulinemia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Agammaglobulinemia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Agammaglobulinemia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Agammaglobulinemia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Agammaglobulinemia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Agammaglobulinemia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Agammaglobulinemia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Agammaglobulinemia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Agammaglobulinemia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Agammaglobulinemia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Agammaglobulinemia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Agammaglobulinemia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Agammaglobulinemia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Agammaglobulinemia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Agammaglobulinemia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Agammaglobulinemia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Agammaglobulinemia - Access and Reimbursement Overview
16 AGAMMAGLOBULINEMIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 AGAMMAGLOBULINEMIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 AGAMMAGLOBULINEMIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 AGAMMAGLOBULINEMIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 AGAMMAGLOBULINEMIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 AGAMMAGLOBULINEMIA - EPIDEMIOLOGY AND PATIENT POPULATION
77.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 AGAMMAGLOBULINEMIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 AGAMMAGLOBULINEMIA - UNMET NEEDS
10 AGAMMAGLOBULINEMIA - KEY ENDPOINTS OF TREATMENT
11 AGAMMAGLOBULINEMIA - MARKETED PRODUCTS
11.1 List of Agammaglobulinemia Marketed Drugs Across the Top 7 Markets
11.1.1 Panzyga (Immune globulin 10%) - Octapharma
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 HyQvia (Immune globulin) -Takeda
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 AGAMMAGLOBULINEMIA - PIPELINE DRUGS
12.1 List of Agammaglobulinemia Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. AGAMMAGLOBULINEMIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. AGAMMAGLOBULINEMIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 AGAMMAGLOBULINEMIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Agammaglobulinemia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Agammaglobulinemia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Agammaglobulinemia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Agammaglobulinemia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Agammaglobulinemia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Agammaglobulinemia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Agammaglobulinemia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Agammaglobulinemia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Agammaglobulinemia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Agammaglobulinemia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Agammaglobulinemia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Agammaglobulinemia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Agammaglobulinemia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Agammaglobulinemia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Agammaglobulinemia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Agammaglobulinemia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Agammaglobulinemia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Agammaglobulinemia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Agammaglobulinemia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Agammaglobulinemia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Agammaglobulinemia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Agammaglobulinemia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Agammaglobulinemia - Access and Reimbursement Overview
16 AGAMMAGLOBULINEMIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 AGAMMAGLOBULINEMIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 AGAMMAGLOBULINEMIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
